XML 65 R44.htm IDEA: XBRL DOCUMENT v3.26.1
Summary of Significant Accounting Policies - Accrued Expenses (Details) - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Summary of Significant Accounting Policies [Abstract]    
Incentive and other compensation costs $ 870,910 $ 650,768
Clinical trial costs 259,293 354,762
Director fees 71,250 70,000
Other 64,320 75,519
Accrued expenses $ 1,265,773 $ 1,151,049